SCHEMBL20028047

SCHEMBL20028047

Cc1ccc(-n2nc(C)cc2C(=O)O)nc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM5A P29375 2/20 0.44
KDM4C Q9H3R0 2/20 0.44
KDM5B Q9UGL1 2/20 0.44
UBE2T Q9NPD8 1/20 0.43
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
HSD17B10 Q99714 1/20 0.42
ALDH1A1 P00352 4/20 0.39
TSHR P16473 3/20 0.39
GRN P28799 1/20 0.39
SORT1 Q99523 1/20 0.39
L3MBTL1 Q9Y468 3/20 0.39
ATM Q13315 1/20 0.39
KDM4E B2RXH2 2/20 0.39
RECQL P46063 2/20 0.39
CTDSP1 Q9GZU7 2/20 0.39
GAA P10253 1/20 0.37
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18622991 0.85 MEN1 (0.46) KDM5AKDM4CKDM5BUBE2TKMT2A
SCHEMBL16660104 0.85 ALDH1A1 (0.42) KDM5AKDM4CKDM5BUBE2TKMT2A
SCHEMBL20028048 0.82 ALDH1A1 (0.51) KMT2AMEN1HSD17B10ALDH1A1TSHR
SCHEMBL20028501 0.82 SMN1; SMN2 (0.46) KMT2AMEN1CYP2C9CYP2C19ALDH1A1
SCHEMBL20027748 0.80 TSHR (0.38) KDM5AKDM4CKDM5BKMT2AMEN1
SCHEMBL20028116 0.79 ALDH1A1 (0.53) KDM5AKDM4CKDM5BKMT2AMEN1
SCHEMBL20028740 0.79 KDM5A (0.43) KDM5AKDM4CKDM5BKMT2AMEN1
SCHEMBL13757324 0.78 UBE2T (0.47) KDM5AKDM4CKDM5BUBE2TKMT2A
SCHEMBL1340789 0.78 KMT2A (0.58) KMT2AMEN1ALDH1A1TSHRGRN
SCHEMBL46302 0.77 UBE2T (0.60) UBE2TKMT2AMEN1CYP2C9CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339130-B1 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2022-05-24 US disclosed
US-10934261-B2 Calpain modulators and therapeutic uses thereof BLADE THERAPEUTICS, INC. (US) 2021-03-02 US disclosed
US-10894776-B2 2021-01-19 US disclosed
WO-2018064119-A1 CALPAIN MODULATORS AND THERAPEUTIC USES THEREOF BLADE THERAPEUTICS, INC. (US) 2018-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10934261-B2 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 KDM5A 4319/4885KDM4C 4329/4885KDM5B 4142/4885
US-10894776-B2 CAPNS1, CAPN9, CAPN2 KDM5A 4088/4885KDM4C 4063/4885KDM5B 3690/4885
US-11339130-B1 Calpain modulators and therapeutic uses thereof CAPNS1, CAPN9, CAPN1 KDM5A 4319/4885KDM4C 4329/4885KDM5B 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.